Insurance Reimbursement by CPT Code Confirmed at U.S. Tertiary Hospital (HOPD)

ROKIT Healthcare, an AI-driven personalized organ regeneration platform specialist, announced on the 16th that it has officially confirmed public insurance reimbursement for its diabetic foot ulcer (DFU) regeneration treatment at a major U.S. tertiary hospital (Hospital Outpatient Department, or HOPD).

This case represents the first instance of ROKIT Healthcare's AI-driven autologous tissue regeneration treatment being recognized as an official medical service within the U.S. public insurance system (CPT codes). As the first-ever public insurance reimbursement for this technology, it is being evaluated as a historic milestone, signifying the entry of AI-based regenerative medicine into the established healthcare system.

ROKIT Healthcare's DFU regeneration treatment demonstrates an average regeneration success rate of 82% with a single procedure, and it can reduce the average cost to one-fourth of traditional amputation or wound care. According to the 2023 paper 'Diabetic Foot Ulcers: A Review' published in JAMA (Journal of the American Medical Association), the annual number of DFU patients in the U.S. is estimated at 1.6 million, indicating that the treatment could lead to very significant cost savings.

Furthermore, it is recognized for aligning with a new paradigm of 'cost-saving medical innovation' that reduces high-cost amputations and inpatient treatments, rather than simply lowering drug prices.

This U.S. insurance reimbursement is expected to accelerate market entry into other regions with high insurance barriers, such as the Middle East and Europe, following its success in South America. Health authorities in various countries are highly likely to evaluate the economic and clinical utility of this autologous tissue regeneration treatment based on the precedent of U.S. CPT code application.

ROKIT Healthcare plans to sequentially commercialize its AI-driven personalized organ regeneration platforms for skin, cartilage, and kidney in the U.S., European, and Middle Eastern markets. This insurance reimbursement is seen as more than just a technological innovation; it is a practical starting point for 'cost innovation,' where AI regenerative medicine begins to change the paradigm of healthcare economics.

"This is the first case of AI-based regenerative medicine being incorporated into the official U.S. institutional insurance system, and it will dramatically accelerate the speed of global insurance approvals," said CEO Seokhwan You. "Through our hyper-personalized platform, which combines AI with autologous regeneration technology, we will fully accelerate the 'transition from an era of mass treatment to an era of personalized regeneration.'"